ALX Oncology Holdings Inc. Common Stock (ALXO)
Stock · NASDAQ · Health Care
$1.06as of 10/16/2026
Price chart
Active signals
ALXO Signal Track Record
How signals performed across all stocks →What ALXO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | +3.1% | 51% | September 18, 2026 |
| Bollinger Band Breakdown | 23 | -8.3% | 39% | September 9, 2026 |
| Bollinger Band Breakout | 18 | +1.2% | 56% | June 26, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -24.4% | 25% | September 9, 2026 |
| Any 20-session window (baseline) | -4.1% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ALXO
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Ev…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 48
- Website
- alxoncology.com/
Fundamentals
- 1-day range
- $0.9305$1.16
- Market cap
- $283.93M
- P/E (trailing)
- —
- P/E (forward)
- -1.97
- EPS (trailing)
- $-1.14
- Dividend yield
- —
- Beta
- 0.54
- Avg. volume
- 1.15M
How ALX Oncology Holdings Inc. Common Stock Makes Money
Where the revenue actually goes — FY2020 annual results
Source: 10-K filed Mar 18, 2021 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
ALX Oncology Holdings Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ALXOALX Oncology Holdings Inc. Common Stock$1.06▲ 6.00%Market cap $283.93MP/E —$0.8617$2.66
- CAMPCAMP4 Therapeutics Corporation Common Stock$3.17▼ 8.12%Market cap $282.25MP/E —$2.86$7.75
- TTRXTurn Therapeutics Inc. Common Stock$10.57▼ 8.80%Market cap $286.26MP/E —$2.57$26.5
- FULCFulcrum Therapeutics Inc. Common Stock$3.65▼ 0.54%Market cap $287.64MP/E —$2.83$15.74
- IMRXImmuneering Corporation Class A Common Stock$3.59▼ 1.37%Market cap $288.55MP/E —$3.6$8.48
- BCYCBicycle Therapeutics plc American Depositary Shares$3.46▼ 3.89%Market cap $277.87MP/E —$3.33$9.08
- EBSEmergent BioSolutions Inc. Common Stock$6.38▼ 11.14%Market cap $273.98MP/E —$4.36$14.06
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ALXO ALX Oncology Holdings Inc. Common Stock | $283.93M | — | $1.06 | ▲ 6.00% | $0.8617$2.66 |
| CAMP CAMP4 Therapeutics Corporation Common Stock | $282.25M | — | $3.17 | ▼ 8.12% | $2.86$7.75 |
| TTRX Turn Therapeutics Inc. Common Stock | $286.26M | — | $10.57 | ▼ 8.80% | $2.57$26.5 |
| FULC Fulcrum Therapeutics Inc. Common Stock | $287.64M | — | $3.65 | ▼ 0.54% | $2.83$15.74 |
| IMRX Immuneering Corporation Class A Common Stock | $288.55M | — | $3.59 | ▼ 1.37% | $3.6$8.48 |
| BCYC Bicycle Therapeutics plc American Depositary Shares | $277.87M | — | $3.46 | ▼ 3.89% | $3.33$9.08 |
| EBS Emergent BioSolutions Inc. Common Stock | $273.98M | — | $6.38 | ▼ 11.14% | $4.36$14.06 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric CancerYahoo · 9/28/2026
- ALX Oncology Holdings Announces Publication Of Clinical Data From Its ASPEN-06 Randomized Phase 2 Clinical Trial In Nature Medicine, Showing Durable Clinical Benefit With Evorpacept In HER2-Positive Gastric CancerBenzinga · 9/28/2026
Insider Activity
Insider Actions →- Wong Shelly · August 17, 2026 · Sale573 @ $1.93
- Jason Lettmann · August 17, 2026 · Sale2.2K @ $1.93
- Wong Shelly · July 1, 2026 · Sale1.4K @ $2.04
- Knight Jeff E. · April 16, 2026 · Grant800.0K
- Barbara Klencke · April 16, 2026 · Grant100.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 93.94M
- Total value held
- $186.01M
- Institutional holders
- 66
- Unknown13.01M
- Unknown13.01M
- Unknown12.88M
- Unknown7.96M
- Unknown5.83M
- Unknown5.73M
- Unknown4.18M
- Unknown3.76M
- Unknown3.18M
- Unknown3.17M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
ALX Oncology reports positive Phase 2 data for evorpacept
ALX Oncology announced that its Phase 2 ASPEN-06 trial data was published in Nature Medicine. The results indicate durable clinical benefit for evorpacept in HER2-positive gastric cancer. This scientific validation provides new context for the stock, which is currently trading near its 52-week low despite an average analyst target of $4.60.
ALX Oncology reports positive Phase 2 data for evorpacept. ALX Oncology announced that its Phase 2 ASPEN-06 trial data was published in Nature Medicine. The results indicate durable clinical benefit for evorpacept in HER2-positive gastric cancer. This scientific validation provides new context for the stock, which is currently trading near its 52-week low despite an average analyst target of $4.60.